Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Account Payables (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Change in Account Payables data on record, last reported at $3.0 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 275.93% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $6.7 million, up 159.57%, while the annual FY2025 figure was $6.7 million, 159.57% up from the prior year.
  • Change in Account Payables reached $3.0 million in Q4 2025 per COLL's latest filing, up from -$3.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $13.9 million in Q1 2025 and bottomed at -$7.0 million in Q2 2025.
  • Average Change in Account Payables over 5 years is -$301650.0, with a median of -$537500.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: tumbled 1150.0% in 2021, then soared 648.86% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$3.5 million in 2021, then decreased by 17.0% to -$4.1 million in 2022, then skyrocketed by 219.6% to $5.0 million in 2023, then plummeted by 83.65% to $810000.0 in 2024, then surged by 275.93% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $3.0 million in Q4 2025, -$3.3 million in Q3 2025, and -$7.0 million in Q2 2025.